Application of monoclonal antibodies against PrPC in preclinical models of cancer cells, such as mesenchymal colon cancer [43] or CSCs–CRC [46], has proven to be a well-founded strategy to mitigate cellular aggressive phenotype with minimal toxicity. Here, PRNP is linked to colonic neoplasm.